206 related articles for article (PubMed ID: 34685571)
21. RAN Translation of the Expanded CAG Repeats in the SCA3 Disease Context.
Jazurek-Ciesiolka M; Ciesiolka A; Komur AA; Urbanek-Trzeciak MO; Krzyzosiak WJ; Fiszer A
J Mol Biol; 2020 Dec; 432(24):166699. PubMed ID: 33157084
[TBL] [Abstract][Full Text] [Related]
22. Mutant Ataxin-3-Containing Aggregates (MATAGGs) in Spinocerebellar Ataxia Type 3: Dynamics of the Disorder.
Raj K; Akundi RS
Mol Neurobiol; 2021 Jul; 58(7):3095-3118. PubMed ID: 33629274
[TBL] [Abstract][Full Text] [Related]
23. Cerebellar soluble mutant ataxin-3 level decreases during disease progression in Spinocerebellar Ataxia Type 3 mice.
Nguyen HP; Hübener J; Weber JJ; Grueninger S; Riess O; Weiss A
PLoS One; 2013; 8(4):e62043. PubMed ID: 23626768
[TBL] [Abstract][Full Text] [Related]
24. Sodium valproate increases activity of the sirtuin pathway resulting in beneficial effects for spinocerebellar ataxia-3 in vivo.
Watchon M; Luu L; Robinson KJ; Yuan KC; De Luca A; Suddull HJ; Tym MC; Guillemin GJ; Cole NJ; Nicholson GA; Chung RS; Lee A; Laird AS
Mol Brain; 2021 Aug; 14(1):128. PubMed ID: 34416891
[TBL] [Abstract][Full Text] [Related]
25. Far-infrared Radiation Improves Motor Dysfunction and Neuropathology in Spinocerebellar Ataxia Type 3 Mice.
Liu SW; Chang JC; Chuang SF; Liu KH; Cheng WL; Chang HJ; Chang HS; Lin TT; Hsieh CL; Lin WY; Hsieh M; Kuo SJ; Liu CS
Cerebellum; 2019 Feb; 18(1):22-32. PubMed ID: 29725949
[TBL] [Abstract][Full Text] [Related]
26. Lysine 117 on ataxin-3 modulates toxicity in
Blount JR; Patel NC; Libohova K; Harris AL; Tsou WL; Sujkowski A; Todi SV
bioRxiv; 2023 Jun; ():. PubMed ID: 37398109
[TBL] [Abstract][Full Text] [Related]
27. Inactivation of PNKP by mutant ATXN3 triggers apoptosis by activating the DNA damage-response pathway in SCA3.
Gao R; Liu Y; Silva-Fernandes A; Fang X; Paulucci-Holthauzen A; Chatterjee A; Zhang HL; Matsuura T; Choudhary S; Ashizawa T; Koeppen AH; Maciel P; Hazra TK; Sarkar PS
PLoS Genet; 2015 Jan; 11(1):e1004834. PubMed ID: 25590633
[TBL] [Abstract][Full Text] [Related]
28. CRISPR/Cas9-Targeted Deletion of Polyglutamine in Spinocerebellar Ataxia Type 3-Derived Induced Pluripotent Stem Cells.
Ouyang S; Xie Y; Xiong Z; Yang Y; Xian Y; Ou Z; Song B; Chen Y; Xie Y; Li H; Sun X
Stem Cells Dev; 2018 Jun; 27(11):756-770. PubMed ID: 29661116
[TBL] [Abstract][Full Text] [Related]
29. Altered retinal structure and function in Spinocerebellar ataxia type 3.
Toulis V; Casaroli-Marano R; Camós-Carreras A; Figueras-Roca M; Sánchez-Dalmau B; Muñoz E; Ashraf NS; Ferreira AF; Khan N; Marfany G; Costa MDC
Neurobiol Dis; 2022 Aug; 170():105774. PubMed ID: 35605759
[TBL] [Abstract][Full Text] [Related]
30. PolyQ-expanded ataxin-3 protein levels in peripheral blood mononuclear cells correlate with clinical parameters in SCA3: a pilot study.
Gonsior K; Kaucher GA; Pelz P; Schumann D; Gansel M; Kuhs S; Klockgether T; Forlani S; Durr A; Hauser S; Rattay TW; Synofzik M; Hengel H; Schöls L; Rieß OH; Hübener-Schmid J
J Neurol; 2021 Apr; 268(4):1304-1315. PubMed ID: 33106888
[TBL] [Abstract][Full Text] [Related]
31.
Lee JH; Lin SY; Liu JW; Lin SZ; Harn HJ; Chiou TW
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34199295
[TBL] [Abstract][Full Text] [Related]
32. Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice.
Toonen LJA; Rigo F; van Attikum H; van Roon-Mom WMC
Mol Ther Nucleic Acids; 2017 Sep; 8():232-242. PubMed ID: 28918024
[TBL] [Abstract][Full Text] [Related]
33. Disulfiram facilitates ataxin-3 nuclear translocation and potentiates the cytotoxicity in a cell model of SCA3.
Wang Z
J Toxicol Sci; 2019; 44(8):535-542. PubMed ID: 31378764
[TBL] [Abstract][Full Text] [Related]
34. Karyopherin α-3 is a key protein in the pathogenesis of spinocerebellar ataxia type 3 controlling the nuclear localization of ataxin-3.
Sowa AS; Martin E; Martins IM; Schmidt J; Depping R; Weber JJ; Rother F; Hartmann E; Bader M; Riess O; Tricoire H; Schmidt T
Proc Natl Acad Sci U S A; 2018 Mar; 115(11):E2624-E2633. PubMed ID: 29476013
[TBL] [Abstract][Full Text] [Related]
35. H1152 promotes the degradation of polyglutamine-expanded ataxin-3 or ataxin-7 independently of its ROCK-inhibiting effect and ameliorates mutant ataxin-3-induced neurodegeneration in the SCA3 transgenic mouse.
Wang HL; Hu SH; Chou AH; Wang SS; Weng YH; Yeh TH
Neuropharmacology; 2013 Jul; 70():1-11. PubMed ID: 23347954
[TBL] [Abstract][Full Text] [Related]
36. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease.
Koch P; Breuer P; Peitz M; Jungverdorben J; Kesavan J; Poppe D; Doerr J; Ladewig J; Mertens J; Tüting T; Hoffmann P; Klockgether T; Evert BO; Wüllner U; Brüstle O
Nature; 2011 Nov; 480(7378):543-6. PubMed ID: 22113611
[TBL] [Abstract][Full Text] [Related]
37. Upregulation of miR-25 and miR-181 Family Members Correlates with Reduced Expression of ATXN3 in Lymphocytes from SCA3 Patients.
Krauss S; Nalavade R; Weber S; Carter K; Evert BO
Microrna; 2019; 8(1):76-85. PubMed ID: 30147021
[TBL] [Abstract][Full Text] [Related]
38. Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3.
Prudencio M; Garcia-Moreno H; Jansen-West KR; Al-Shaikh RH; Gendron TF; Heckman MG; Spiegel MR; Carlomagno Y; Daughrity LM; Song Y; Dunmore JA; Byron N; Oskarsson B; Nicholson KA; Staff NP; Gorcenco S; Puschmann A; Lemos J; Januário C; LeDoux MS; Friedman JH; Polke J; Labrum R; Shakkottai V; McLoughlin HS; Paulson HL; Konno T; Onodera O; Ikeuchi T; Tada M; Kakita A; Fryer JD; Karremo C; Gomes I; Caviness JN; Pittelkow MR; Aasly J; Pfeiffer RF; Veerappan V; Eggenberger ER; Freeman WD; Huang JF; Uitti RJ; Wierenga KJ; Marin Collazo IV; Tipton PW; van Gerpen JA; van Blitterswijk M; Bu G; Wszolek ZK; Giunti P; Petrucelli L
Sci Transl Med; 2020 Oct; 12(566):. PubMed ID: 33087504
[TBL] [Abstract][Full Text] [Related]
39. T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse.
Chou AH; Chen YL; Chiu CC; Yuan SJ; Weng YH; Yeh TH; Lin YL; Fang JM; Wang HL
Neuropharmacology; 2015 Dec; 99():308-17. PubMed ID: 26254860
[TBL] [Abstract][Full Text] [Related]
40. The Josephin domain (JD) containing proteins are predicted to bind to the same interactors: Implications for spinocerebellar ataxia type 3 (SCA3) studies using
Sousa E Silva R; Sousa AD; Vieira J; Vieira CP
Front Mol Neurosci; 2023; 16():1140719. PubMed ID: 37008788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
